prikaz prve stranice dokumenta MiR-182-5p and miR-375-3p Have Higher Performance Than PSA in Discriminating Prostate Cancer from Benign Prostate Hyperplasia
  Preuzmi
PDF 1.09 MB
Znanstveni rad - Izvorni znanstveni rad
MiR-182-5p and miR-375-3p Have Higher Performance Than PSA in Discriminating Prostate Cancer from Benign Prostate Hyperplasia
Cancers, 13 (2021), 9; 2068. https://doi.org/10.3390/cancers13092068
Abramović, Irena; Vrhovec, Borna; Škara, Lucija; Vrtarić, Alen; Nikolac Gabaj, Nora; Kuliš, Tomislav; Štimac, Goran; Ljiljak, Dejan; Ružić, Boris; Kaštelan, Željko; Krušlin, Božo; Bulić-Jakuš, Floriana; Ulamec, Monika; Katušić-Bojanac, Ana; Sinčić, Nino Više autora...

Institucijski repozitorij: Repozitorij stomatološkog fakulteta u Zagrebu

Citirajte ovaj rad

Abramović, I., Vrhovec, B., Škara, L., Vrtarić, A., Nikolac Gabaj, N., Kuliš, T. ... Sinčić, N. (2021). MiR-182-5p and miR-375-3p Have Higher Performance Than PSA in Discriminating Prostate Cancer from Benign Prostate Hyperplasia. Cancers, 13. (9). doi: 10.3390/cancers13092068

Abramović, Irena, et al. "MiR-182-5p and miR-375-3p Have Higher Performance Than PSA in Discriminating Prostate Cancer from Benign Prostate Hyperplasia." Cancers, vol. 13, br. 9, 2021. https://doi.org/10.3390/cancers13092068

Abramović, Irena, Borna Vrhovec, Lucija Škara, Alen Vrtarić, Nora Nikolac Gabaj, Tomislav Kuliš, Goran Štimac, et al. "MiR-182-5p and miR-375-3p Have Higher Performance Than PSA in Discriminating Prostate Cancer from Benign Prostate Hyperplasia." Cancers 13, br. 9 (2021). https://doi.org/10.3390/cancers13092068

Abramović, I., et al. (2021) 'MiR-182-5p and miR-375-3p Have Higher Performance Than PSA in Discriminating Prostate Cancer from Benign Prostate Hyperplasia', Cancers, 13(9). doi: 10.3390/cancers13092068

Abramović I, Vrhovec B, Škara L, Vrtarić A, Nikolac Gabaj N, Kuliš T, i sur.. MiR-182-5p and miR-375-3p Have Higher Performance Than PSA in Discriminating Prostate Cancer from Benign Prostate Hyperplasia. Cancers [Internet]. 25.04.2021. [pristupljeno 27.12.2024.];13(9). doi: 10.3390/cancers13092068

I. Abramović, et al., "MiR-182-5p and miR-375-3p Have Higher Performance Than PSA in Discriminating Prostate Cancer from Benign Prostate Hyperplasia", Cancers, vol. 13, br. 9, Travanj 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:127:178318. [Citirano: 27.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:127:178318
Podaci o radu
Naslov (engleski)MiR-182-5p and miR-375-3p Have Higher Performance Than PSA in Discriminating Prostate Cancer from Benign Prostate Hyperplasia
AutorIrena Abramović
AutorBorna Vrhovec
AutorLucija Škara
AutorAlen Vrtarić
AutorNora Nikolac Gabaj
AutorTomislav Kuliš
AutorGoran Štimac
AutorDejan Ljiljak
AutorBoris Ružić
AutorŽeljko Kaštelan
AutorBožo Krušlin
AutorFloriana Bulić-Jakuš
AutorMonika Ulamec
AutorAna Katušić-Bojanac
AutorNino Sinčić
Autorova ustanova(Klinički bolnički centar Sestre milosrdnice)
Autorova ustanova(Klinički bolnički centar Zagreb)
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
Autorova ustanovaSveučilište u Zagrebu
Stomatološki fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
Prostate cancer (PCa) is the most commonly diagnosed neoplasm among men. Since it often resembles benign prostate hyperplasia (BPH), biomarkers with a higher differential value than PSA are required. Epigenetic biomarkers in liquid biopsies, especially miRNA, could address this challenge. The absolute expression of miR-375-3p, miR-182-5p, miR-21-5p, and miR-148a-3p were quantified in blood plasma and seminal plasma of 65 PCa and 58 BPH patients by digital droplet PCR. The sensitivity and specificity of these microRNAs were determined using ROC curve analysis. The higher expression of miR-182-5p and miR-375-3p in the blood plasma of PCa patients was statistically significant as compared to BPH (p = 0.0363 and 0.0226, respectively). Their combination achieved a specificity of 90.2% for predicting positive or negative biopsy results, while PSA cut-off of 4 µg/L performed with only 1.7% specificity. In seminal plasma, miR-375-3p, miR-182-5p, and miR-21-5p showed a statistically significantly higher expression in PCa patients with PSA >10 µg/L compared to ones with PSA ≤10 µg/L. MiR-182-5p and miR-375-3p in blood plasma show higher performance than PSA in discriminating PCa from BPH. Seminal plasma requires further investigation as it represents an obvious source for PCa biomarker identification.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaCancers
Brojčani podacivol. 13, br. 9, 2068
e-ISSN2072-6694
DOIhttps://doi.org/10.3390/cancers13092068
URN:NBNurn:nbn:hr:127:178318
Datum objave publikacije2021-04-25
URL dokumentahttps://www.mdpi.com/2072-6694/13/9/2068
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2022-11-10 10:55:49